iBio, Inc.
9 Innovation Way
Suite 100
Newark,
DE 19711
United States - Map
Phone: 302-355-0650
Fax: 302-356-1173
Web Site: http://www.ibioinc.com
| iBio, Inc., a biopharmaceutical company, focuses on the development of vaccines and therapeutic proteins based upon its proprietary plant-based iBioLaunch Platform Technology. The company principally focuses on advancing a H1N1 influenza vaccine candidate to clinical trials and to establish business arrangements for use of the technology by licensees for the development and production of other products for the prevention and treatment of various infectious diseases, including influenza, anthrax, and human papilloma virus. iBio holds a research and development agreement with the Fraunhofer USA Center for Molecular Biotechnology and has exclusive rights to the proprietary platform developed under the agreement for human health applications for developing vaccines and therapeutic products for a broad range of medical indications and for veterinary applications of plant-based influenza vaccines. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio is headquartered in Newark, Delaware. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Robert B. Kay , 69
Exec. Chairman and Chief Exec. Officer |
$
200.00K | N/A | Mr. Robert L. Erwin , 55
Pres |
$
200.00K | N/A | Mr. Frederick Larcombe CPA, 52
Chief Financial Officer and Chief Accounting Officer |
N/A
| N/A | Dr. Geoffrey Schild Ph.D., CBE, 72
Chief Scientific Officer |
N/A
| N/A | Ms. Jennifer L. Kmiec , 49
VP of Bus. Devel. & Marketing |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-09
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.29% Nasdaq 0.00%
Profile
